SCHEMBL11078484

SCHEMBL11078484

O=[As](O)(O)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.56
KDM4E B2RXH2 1/20 0.56
RAB9A P51151 1/20 0.56
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
ALDH1A1 P00352 3/20 0.54
TP53 P04637 2/20 0.54
CYP2C19 P33261 2/20 0.54
ALOX15 P16050 2/20 0.54
CYP2C9 P11712 1/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TASP1 Q9H6P5 1/20 0.54
MAPT P10636 2/20 0.46
KMT2A Q03164 3/20 0.45
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22999953 0.85 KDM4E (0.72) TSHRKDM4ERAB9ACA4CA6
SCHEMBL9167276 0.83 TDP1 (0.50) TSHRKDM4ERAB9ACA4CA6
SCHEMBL23000006 0.77 KDM4E (0.62) TSHRKDM4ERAB9ACA4CA6
SCHEMBL9175879 0.75 TDP1 (0.65) TSHRCA4CA6CA7CA9
SCHEMBL3056859 0.74 MAPT (0.74) TSHRKDM4ERAB9ACA4CA6
Arsanilic Acid SCHEMBL160507 0.72 KDM4E (1.00) TSHRKDM4ERAB9ACA4CA6
SCHEMBL11034243 0.72 TSHR (0.56) TSHRKDM4ERAB9ACA4CA6
SCHEMBL20916723 0.72 KDM4E (0.56) TSHRKDM4ERAB9ACA4CA6
SCHEMBL20916722 0.72 KDM4E (0.56) TSHRKDM4ERAB9ACA4CA6
Arsanilic Acid SCHEMBL4837583 0.72 KDM4E (1.00) TSHRKDM4ERAB9ACA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3676282-B1 ANTI-CANCER AGENT UNIV WOLLONGONG (AU) 2024-11-06 EP disclosed
CN-111344298-B Anticancer agent 伍伦贡大学 2024-05-28 CN disclosed
US-11819489-B2 Anti-cancer agent comprising a tumour homing peptide having arsenic bonded to cysteine residues UNIVERSITY OF WOLLONGONG (AU) 2023-11-21 US disclosed
US-20210205259-A1 ANTI-CANCER AGENT UNIVERSITY OF WOLLONGONG (AU) 2021-07-08 US disclosed
EP-3676282-A1 ANTI-CANCER AGENT University of Wollongong (AU) 2020-07-08 EP disclosed
CN-111344298-A Anticancer agent 伍伦贡大学 2020-06-26 CN disclosed
WO-2019075507-A9 ANTI-CANCER AGENT UNIVERSITY OF WOLLONGONG (AU) 2020-05-22 WO disclosed
WO-2019075507-A1 ANTI-CANCER AGENT UNIVERSITY OF WOLLONGONG (AU) 2019-04-25 WO disclosed
EP-0070155-B1 PROCESS OF PREPARING A KETAZINE FROM A KETONE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1984-10-10 EP disclosed
US-4473708-A REACTING KETONE WITH AMMONIA AND HYDROGEN PEROXIDE MITSUBISHI GAS CHEMICAL COMPANY INC. (JP) 1984-09-25 US disclosed
US-4374242-A INTERCALATION COMPOUNDS; ADSORBERS; ION EXCHANGERS; REDEX CATALYSTS OCCIDENTAL RESEARCH CORPORATION (US) 1983-02-15 US disclosed
EP-0070155-A1 Process of preparing a ketazine from a ketone MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1983-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210205259-A1 ANTI-CANCER AGENT CCL2, CD44, CXCL12 TSHR 2233/4885KDM4E 4367/4885RAB9A 1496/4885
US-11819489-B2 Anti-cancer agent comprising a tumour homing peptide having arsenic bonded to cysteine residues CCL2, AS3MT, CXCL12 TSHR 2157/4885KDM4E 4569/4885RAB9A 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.